ProfiZYMVyvážený komplex
Kde Kúpiť Kde Kúpiť ProfiZYM Plus Krabička
Čo je ProfiZYM
Ako to funguje
Charakteristika
Dávkovanie
Časté otázky
Krabička ProfiZYM
 
profizym

Referencie

· Raskin JB. Gastrointestinal effects of nonsteroidal anti-inflammatory therapy. Am J Med. 1999; 106 (5B):3S-12S.

· No author listed. Regular Use of Pain Relievers Can Have Dangerous Results. Kaleidoscope Interactive News, American Medical Association media briefing. July 24, 1997.

· Fung HB, Kirschenbaum, HL. Selective cyclooxygenase-2 inhibitors for the treatment of arthritis. Clin Ther. 1999; 21(7):1131-57.

· Geis GS. Update on clinical developments with celecoxib, a new specific COX-2 inhibitor: what can we expect? Scand J Rheumatol Suppl. 1999; 109:31-7.

· Cheatum DE, Arvanitakis C, Gumpel M, Stead H, Geis GS. An endoscopic study of gastroduodenal lesions induced by nonsteroidal anti-inflammatory drugs. Clin Ther. 1999; 21(6):992-1003.

· Tibble JA, Sigthorsson G, Foster R, Scott D, Fagerhol MK, Roseth A, Bjarnason I. High prevalence of NSAID enteropathy as shown by a simple faecal test. Gut. 1999; 45(3):362-6.

· Dingle JT. The effects of NSAID on the matrix of human articular cartilages. Z Rheumatol. 1999; 58(3):125-9.

· Murphy PJ, Badia P, Myers BL, Boecker MR, Wright KP Jr. Nonsteroidal anti-inflammatory drugs affect normal sleep patterns in humans. Physiol Behav. 1994; 55(6):1063-6.

· Metz SA, Robertson RP, Fujimoto WY. Inhibition of prostaglandin E synthesis augments glucose-induced insulin secretion in cultured pancreas. Diabetes. 1981; 30(7):551-7.

· Marriott C. Modification in the rheological properties of mucus by drugs. Adv Exp Med Biol. 1982; 144:75-84.

· Tokumine F, Sunagawa T, Shiohira Y, Nakamoto T, Miyazato F, Muto Y. Drug-associated cholelithiasis: a case of sulindac stone formation and the incorporation of sulindac metabolites into the gallstones. Am J Gastroenterol. 1999;94(8):2285-8.

· Jiang HK, Chang DM. Non-steroidal anti-inflammatory drugs with adverse psychiatric reactions: five case reports. Clin Rheumatol. 1999;18(4):339-45.

· Fung HB, Kirschenbaum, HL. Selective cyclooxygenase-2 inhibitors for the treatment of arthritis. Clin Ther. 1999; 21(7):1131-57.

· FDA MedWatch: The FDA Medical Products Reporting Program. May 12, 1999. FDA Talk Paper.

· Moriya N, Nakata M, Nakamura M, Takaoka M, Iwasa S, Kato K, Kakinuma A. Intestinal absorption of serrapeptase (TSP) in rats. Biotechnol Appl Biochem. 1994; 20(Pt1):101-8.

· Miyata, K. Intestinal absorption of Serratia Peptidase. J Appl Biochem. 1980;2:111-16.

· Perna L. Osservazionl Clniche sui traitamento in osppio cleco con Serratio peptidasl nella neifre perenna naila ninite cronica nacutizzata con sinusopattia, nella bronchia cronica nacutizzata. Rlv Pat Clin Tuberc Penumol. 1985; 56:509-516.

· www.wobenzym.cz

· Mazzone A, et al. Evaluation of Serratia peptidase in acute or chronic inflammation of otorhinolaryngology pathology: a multicentre, double-blind, randomized trial versus placebo. J Int Med Res. 1990; 18(5):379-88.

· Aso T et al. Breast engorgement and its treatment: Clinical effects of Danzen an anti-inflammatory enzyme preparation. The world of Obstetrics and Gynecology (Japanese). 1981; 33:371-9.

· Esch PM, Gerngross H, Fabian A. Reduction of postoperative swelling. Objective measurement of swelling of the upper ankle joint in treatment with serrapeptase-a prospective study (German). Fortschr Med. 1989;107(4):67-8, 71-2.

· Kee WH, Tan SL, Lee V, Salmon YM. The treatment of breast engorgement with Serrapeptase (Danzen): a randomized double-blind controlled trial. Singapore Med J. 1989;30(1):48-54.

· Koyama A, Mori J, Tokuda H, Waku M, Anno H, Katayama T, Murakami K, Komatsu H, Hirata M, Arai T, et al. Augmentation by serrapeptase of tissue permeation by cefotiam (Japanese). Jpn J Antibiot. 1986; 39(3):761-71.

· Majima Y, Inagaki M, Hirata K, Takeuchi K, Morishita A, Sakakura Y. The effect of an orally administered proteolytic enzyme on the elasticity and viscosity of nasal mucus. Arch Otorhinolaryngol. 1988;244(6):355-9.

· Brewer Science Library website. 1999.

· Tomoda K, and Miyatam K. Some information on the composition of trachael secretions before and after the administration of Danzen. Exper Ther. 1972; 477:9-16

· Kase Y, et al. A new method for evaluating mucolytic expectorant activity and its application to two proteolytic enzymes, serratiopeptidase and seaprose. Arznelrnitteltorachung. 1982; 32:374-378.

· Selan L, Berlutti F, Passariello C, Comodi-Ballanti MR, Thaller MC. Proteolytic enzymes: a new treatment strategy for prosthetic infections? Antimicrob Agents Chemother. 1993; 37(12):2618-21.

• Clement DL. Management of venous edema: insights from an international task force. Angiology. 2000; 51:13-17.

• Cruz T, Galvez J, Ocete MA, et al. Oral administration of rutoside can ameliorate inflammatory bowel disease in rats. Life Sci . 1998; 62:687-695.

• Deschner EE, Ruperto JF. Wong GY, Newmark HL. The effect of dietary quercetin and rutin on AOM-induced acute colonic epithelial abnormalities in mice fed a high-fat diet. Nutr Cancer . 1993; 20:199-204.

• Drewa G, Schachtschabel DO, Palgan K, et al. The influence of rutin on the weight, metastasis and melanin content of B16 melanotic melanoma in C57BL/6 mice. Neoplasma . 1998; 45:266-271.

• Galvez J, Cruz T, Crespo E, et al. Rutoside as mucosal protective in acetic acid-induced rat colitis. Planta Med. 1997; 63:409-414.

• Kostyuk VA, Potapovich AI. Antiradical and chelating effects in flavonoid protection against silica-induced cell injury. Arch Biochem Biophys . 1998; 355:43-48.

• Kostyuk VA, Potapovich AI, Speransky SD, Maslova GT. Protective effect of natural flavonoids on rat peritoneal macrophages injury caused by asbestos fiber. Free Rad Biol Med . 1996; 21:487-493.

• Olthof MR, Hollman PC, Vree TB, Katan MB. Bioavailabilities of quercetin-3-glucoside and quercetin-4'-glucoside do not differ in humans. J Nutr. 2000; 130:1200-1203.

• Park JB, Levine M. Intracellular accumulation of ascorbic acid is inhibited by flavonoids via blocking of dehydroascorbic acid and ascorbic acid uptakes in HL-60, U937 and Jurkat cells. J Nutr . 2000; 130:1297-1302.

• Perez Guerrero C, Martin MG, Marhuenda E. Prevention by rutin of gastric lesions induced by ethanol in rats: role of endogenous prostaglandins. Gen Pharmacol. 1994; 25:575-580.

• Rueff J, Gaspar J, Laires A. Structural requirements for mutagenicity of flavonoids upon nitrosation. A structure-activity study. Mutagenesis . 1995; 10:325-328.

• Schmitt A, Savayre R, Delchambre J, Negre-Salvayre A. Prevention by alpha-tocopherol and rutin of glutathione and ATP depletion induced by oxidized LDL in cultured endothelial cells. Br J Pharmacol. 1995; 116:1985-1990.

• Webster RP, Gawde MD, Bhattacharya RK, Protective effect of rutin, a flavonol glycoside, on the carcinogen-induced DNA damage and repair enzymes in rats. Cancer Lett . 1996; 109:185-191.

• Anton R, Beretz A. Flavonoids: antithrombotic agents or nutrients ? Bull Acad Natl Med 1990 Jun-Jul;174(6):709-14; discussion 714-7

• Chen YT, Zheng RL, Jia ZJ, Ju Y. Flavonoids as superoxide scavengers and antioxidants. Free Radic Biol Med 1990;9(1):19-21

• Robak J, Gryglewski RJ. Bioactivity of flavonoids. Pol J Pharmacol 1996 Nov-Dec;48(6) :555-64

• Shimoi K, Masuda S, Shen B, Furugori M, Kinae N. Radioprotective effects of antioxidative plant flavonoids in mice. Radioprotective effects of antioxidative plant flavonoids in mice.

• Vinson JA. Flavonoids in foods as in vitro and in vivo antioxidants. Adv Exp Med Biol 1998;439:151-64

• Asgary S. Naderi G. Et al. Anti-oxidant effect of flavonoids on hemoglobin glycosylation. Pharm Acta Helv 1999 Feb;73(5):223-6

• Rowan AD, Buttle DJ, Barrett AJ. The cysteine proteinases of the pineapple plant. Biochem J 1990;266:869-875.

• Taussig SJ, Nieper HA. Bromelain: its use in prevention and treatment of cardiovascular disease, present status. J IAPM 1979;6:139-151.

• Harrach T, Eckert K, Schulze-Forster K, et al. Isolation and partial characterization of basic proteinases from stem bromelain. J Protein Chem 1995;14:41-52.

• Jeung A. Encyclopedeia of Common Natural Ingredients Used in Foods, Drugs, and Cosmetics. New York, NY: John Wiley & Sons;1980:74-76.

 

• White RR, Crawley FE, Vellini M, et al. Bioavailability of 125I bromelain after oral administration to rats. Biopharm Drug Dispos 1988;9:397-403.

• Heinicke RM, Van der Wal M, Yokoyama MM. Effect of bromelain on human platelet aggrega tion. Experientia 1972;28:844-845.

• Morita AH, Uchida DA, Taussig SJ. Chromato graphic fractionation and characterization of the active platelet aggregation inhibitory factor from bromelain. Arch Inter Phar Ther 1979;239:340-350.

• Livio M, Bertoni MP, De Gaetano G, et al. Effect of bromelain on fibrinogen level, prothrombin complex factors and platelet aggregation in the rat - A preliminary report. Drugs Expt Clin Res 1978;4:49-53.

• De-Giuli M, Pirotta F. Bromelain: interaction with some protease inhibitors and rabbit specific antiserum. Drugs Exp Clin Res 1978;4:21-23.

• Inoue K, Motonaga A, Dainaka J, et al. Effect of etodolac on prostaglandin E2 biosynthesis, active oxygen generation and bradykinin formation. Prostaglandins Leukot Essent Fatty Acids 1994;51:457-462.

• Uhlig G, Seifert J. The effect of proteolytic enzymes (traumanase) on posttraumatic edema. Fortschr Med 1981;99:554-556.

• Vellini M, Desideri D, Milanese A, et al. Possible involvement of eicosanoids in the pharmacological action of bromelain. Arzneimittelforschung 1986;36:110-112.

• Yonehara N, Shibutani T, Inoki R. Contribution of substance P to heat-induced edema in rat paw. J Pharmacol Exp Ther 1987;242:1071-1076.

• Kumakura S, Yamashita M, Tsurufuji S. Effect of bromelain on kaolin-induced inflammation in rats. Eur J Pharmacol 1988;150:295-301.

• Uchida Y, Katori M. Independent consumption of high and low molecular weight kininogens in vivo. Adv Exp Med Biol 1986;198:113-118.

• Taussig SJ, Batkin S. Bromelain, the enzyme complex of pineapple (Ananas comosus) and its clinical application. An update. J Ethnopharmacol 1988;22:191-203.

• Schafer A, Adelman B. Plasmin inhibition of platelet function and of arachidonic acid metabolism. J Clin Invest 1985;75:456-461.

• Felton GE. Fibrinolytic and antithrombotic action of bromelain may eliminate thrombosis in heart patients. Med Hypotheses 1980;6:1123-1133.

• Gerard G. Anti-cancer therapy with bromelain. Agress 1972;3:261-274.

• Nieper HA. A program for the treatment of cancer. Krebs 1974;6:124-127.

• Taussig SJ, Szekerczes J, Batkin S. Inhibition of tumor growth in vitro by bromelain, an extract of the pineapple plant (Ananas comosus). Planta Med 1985;6:538-539.

• Batkin S, Taussig SJ, Szekerezes J. Antimetastatic effect of bromelain with or without its proteolytic and anticoagulant activity. J Cancer Res Clin Oncol 1988;114:507.

• Desser L, Rehberger A, Paukovits W. Proteolytic enzymes and amylase induce cytokine production in human peripheral blood mononuclear cells in vitro. Cancer Biother 1994;9:253-263.

• Desser L, Rehberger A. Induction of tumor necrosis factor in human peripheral-blood mononuclear cells by proteolytic enzymes. Oncology 1990;47:475-477.

• Desser L, Rehberger A, Kokron E, et al. Cytokine synthesis in human peripheral blood mononuclear cells after oral administration of polyenzyme preparations. Oncology 1993;50:403-407.

• Munzig E, Eckert K, Harrach T, et al. Bromelain protease F9 reduces the CD44 mediated adhesion of human peripheral blood lymphocytes to human umbilical vein endothelial cells. FEBS Lett 1995;351:215-218.

• Houck JC, Chang CM, Klein G. Isolation of an effective debriding agent from the stems of pineapple plants. Int J Tissue React 1983;5:125-134.

• Klaue P, Dilbert G, Hinke G, et al. Tier-experimentelle untersuchungen zur enzymatischen lokalbehandlung subdermaler verbrennungen mit bromelain. Therapiewoche 1979;29:796-799.

• Ahle NW, Hamlet MP. Enzymatic frostbite eschar debridement by bromelain. Ann Emerg Med 1987;16:1063-1065.

• Moss JN, Frazier CV, Martin GJ. Bromelains, the pharmacology of the enzymes. Arch Int Pharmacodyn 1963;145:168.

• Tinozzi S, Venegoni A. Effect of bromelain on serum and tissue levels of amoxycillin. Drugs Expt Clin Res 1978;4:39-44.

• Luerti M, Vignali ML. Influence of bromelain on penetration of antibiotics in uterus, salpinx and ovary. Drugs Expt Clin Res 1978;4:45-48.

• Renzinni G, Varengo M. The absorption of tetracyclin in conbination with bromelain by oral application. Arzneim-Forsch 1972;22:410-412.

• Neubauer RA. A plant protease for potentiation of and possible replacement of antibiotics. Exp Med Surg 1961;19:143-160

• Ryan RE. A double-blind clinical evaluation of bromelains in the treatment of acute sinusitis. Headache 1967;7:13-17.

• Hunter RG, Henry GW, Heinicke RM. The action of papain and bromelain on the uterus. Am J Ob Gyn 1957;73:867-873.

• Suzuki K, Niho T, Yamada H, et al. [Experimental study of the effects of bromelain on the sputum consistency in rabbits]. Nippon Yakurigaku Zasshi 1983;81:211-216.

• Knill-Jones RP, Pearce H, Batten J, et al. Comparative trial of Nutrizym in chronic pancreatic insufficiency. Brit Med J 1970;4:21.

• Balakrishnan V, Hareendran A, Sukumaran Nair C. Double-blind cross-over trial of an enzyme preparation in pancreatic steatorrhea. J Asso Phys Ind 1981;29:207-209.

• Seligman B. Bromelain-an anti-inflammatory agentNthrombophlebitis. No toxicity. Angiology 1962;13:508-510.

• Felton G. Does Kinin released by pineapple stem bromelain stimulate production of prostaglandin E1-like compound. Haw Med J 1976;2:39-47.

• Mynott TL, Luke RK, Chandler DS. Oral administration of protease inhibits enterotoxigenic Escherichia coli receptor activity in piglet small intestine. Gut 1996;38:28-32.

• Blonstein JL. Control of swelling in boxing injuries. Practitioner 1960;185:78.

• Tassman GC, Zafran JN, Zayon GM. Evaluation of a plant proteolytic enzyme for the control of inflammation and pain. J Dent Med 1964;19:73-77. oral surgery. J Dent Med 1965;20:51-54.

• Masson M. Bromelain in blunt injuries of the locomotor system. A study of observed applications in general practice. Fortschr Med 1995;113:303-306.

• Giacca S. Clinical experiments with bromelain in peripheral venous diseases and chronic bronchitic states. Minerva Med 1965;56:Suppl.104.

• Nieper HA. Effect of bromelain on coronary heart disease and angina pectoris. Acta Med Empirica 1978;5:274-278.

• Nieper HA. Decrease of the incidence of coronary heart infarct by Mg- and K-orotate and bromelain. Acta Med Empirica 1977;12:614-618.

• Seligman B. Oral bromelains as adjuncts in the treatment of acute thrombophlebitis. Angiology 1969;20:22-26.

• Taussig SJ, Yokoyama MM, Chinen N, et al. Bromelain: A proteolytic enzyme and its clinical application. HirJ Med Sci 1975;24:185-193.

• Gutfreund A, Taussig S, Morris A. Effect of oral bromelain on blood pressure and heart rate of hypertensive patients. Haw Med Jour 1978;37:143-146.

• Gailhofer G, Wilders-Truschnig M, Smolle J, Ludvan M. Asthma caused by bromelain: an occupational allergy. Clin Allergy 1988;18:445-450.

• Chida T. A study on dose-response relationship of occupational allergy in a pharmaceutical plant. Sangyo Igaku 1986;28:77-86.

• Tretter V, Altmann F, Kubelka V, et al. Fucose alpha 1,3-linked to the core region of glycoprotein N-glycans creates an important epitope for IgE from honeybee venom allergic individuals. Int Arch Allergy Immunol 1993;102:259-266.

• Batanero E, Villalba M, Monsalve RI, et al. Cross-reactivity between the major allergen from olive pollen and unrelated glycoproteins: evidence of an epitope in the glycan moiety of the allergen. J Allergy Clin Immunol 1996;97:1264-1271.

• Wuthrich B. Proteolytic enzymes: potential allergens for the skin and respiratory tract?

profizym
 

Stada

STADA PHARMA Slovakia, s.r.o., Einsteinova 19, 851 01 Bratislava
Ladival OralZYM